During the past year, said Michael, CordenPharma has achieved remarkable milestones in the pharmaceutical and biotech industry.
The company’s involvement in launching innovative medicines for both orphan diseases and larger conditions, such as diabetes, showcases our commitment to making a significant impact on patients’ lives.
The excitement about our products and innovations is evident, with substantial investments being made to expand our capabilities.
Our ambitious €500m CapEx expansion programme during the next 3 years, especially in key areas such as small to large-scale peptides, oligonucleotides, lipid nanoparticle (LNP) formulation, specialised lipid excipients and new offerings for highly potent and oncology oral solid dosage (OSD) manufacturing, is setting the stage for continued growth to meet the market demand in those important areas.
We also have a continued focus on sustainability, as demonstrated by our participation in the Science-Based Targets initiative (SBTi), where we are committed to reducing global emissions by evaluating and setting science-based reduction targets which reflect an ongoing, proactive approach to environmental responsibility.
In addition, we have utilised green technologies — such as innovative methods to recycle solvents, supercritical fluid chromatography (SFC) and continuous manufacturing — to demonstrate our commitment to ESG manufacturing processes, which is increasingly essential in all global industries, including the life sciences.
Key takeaways on the agenda at CPHI Barcelona included supply chain resilience and diversification, which are critically important topics for our customers.
CordenPharma’s ability to support a resilient supply chain and drive innovation with greener manufacturing processes is highly valued by clients, as the whole world continues to face geopolitical challenges and sustainability concerns.
Ultimately, CordenPharma’s CDMO success goes beyond capacity. It’s rooted in its dedicated team, close collaboration with customers and unique capability to provide end-to-end solutions from early stage to the commercial production of APIs and drug products; all of this ensures that we not only meet our customers’ needs but provide the added value that supports getting their products to market efficiently and competitively.
As we look ahead to 2024, our commitment to innovation, sustainability, and customer-centric solutions will continue to drive our success in the pharmaceutical industry.
